How to Buy Aurinia Pharmaceuticals Stock
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
Aurinia Pharmaceuticals stock last closed at $9.05, up 1.17% from the previous day, and has increased 61.03% in one year. It has overperformed other stocks in the Biotechnology industry by 1.29 percentage points. Aurinia Pharmaceuticals stock is currently +74.21% from its 52-week low of $5.20, and -15.18% from its 52-week high of $10.67.
There are currently 135.1M shares of AUPH outstanding. The market capitalization of AUPH is $1.22B. In the last 24 hours, 2.05M AUPH shares were traded.
How to Buy Aurinia Pharmaceuticals Stock
Wondering how to invest in Aurinia Pharmaceuticals stock? Here's how.
- Figure out where to buy Aurinia Pharmaceuticals stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Aurinia Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your brokerage account: Pick your method of payment and add your details.
- Analyze Aurinia Pharmaceuticals stock: The Aurinia Pharmaceuticals ticker symbol is AUPH. Is Aurinia Pharmaceuticals stock a good investment? Should you buy shares of AUPH? How do AUPH's underlying business fundamentals look? Do top analysts think Aurinia Pharmaceuticals is a good buy? Why has AUPH's stock price moved recently? (Hint: Our stock market analysis tools can help you figure out if AUPH is a good stock to buy).
- Place your AUPH purchase: Decide if you will purchase AUPH shares at the current market price or use a limit order to buy AUPH stock at a specific price.
- Keep tabs on your investment in AUPH: Create a watchlist to monitor your position in Aurinia Pharmaceuticals stock.
Step 1: Figure out where to buy Aurinia Pharmaceuticals stock
You will need a brokerage account in order to access the NASDAQ market and buy AUPH stock.
Our recommended brokerage: eToro
We believe that eToro is the best brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Utilities, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal information so you can buy AUPH stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open your new trading account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've finished signing up on the best stock market app, you can securely and quickly fund your account:
Watch the tutorial below if you need help depositing funds into your brokerage account.
Step 4: Analyze Aurinia Pharmaceuticals stock
After you have decided on the best place to buy Aurinia Pharmaceuticals stock, it's very important to research their stock before you invest, so you actually understand the risk as well as the opportunity.
Aurinia Pharmaceuticals stock quick numbers
Aurinia Pharmaceuticals Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on AUPH's stock page.
Is AUPH stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge AUPH's intrinsic value.
Using relative valuations methods:
- AUPH may be undervalued based on its P/E ratio of 31.21x, relative to Biotechnology industry P/E ratio of -199.97x
- AUPH may be undervalued based on its P/B ratio of 3.49x, relative to Biotechnology industry P/B ratio of 4.34x
- AUPH may be undervalued based on its PEG ratio of 0.49x
You can do additional valuation research on AUPH's stock here.
AUPH Financial Health
Positive Financial Indicators:
- AUPH earnings of $46.43M is not sufficient to cover its interest payments.
- AUPH profit margin has gone up from -32.7% to 16.1% in the past year.
- There are more short-term assets than long-term liabilities on the AUPH balance sheet.
- AUPH's operating cash flow of $64.29M allows it to safely service it's debt of $77.91M.
- There are more short-term assets than short-term liabilities on the AUPH balance sheet.
Negative Financial Indicators:
- AUPH has a relatively high debt to equity ratio of 0.44.
- Total AUPH debt is higher than 5 years ago, relative to shareholder equity.
Is AUPH stock a Buy, Hold, or Sell, according to analysts?
Out of 1 sell side analysts who give recommendations on AUPH, the consensus analyst rating on AUPH is a Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Aurinia Pharmaceuticals stock forecast page.
AUPH Trading Indicators
AUPH Earnings
Last year, AUPH revenue was $247.30M. Over the past 5 year, AUPH's revenue has increased by 278.58% per year. This was faster than the Biotechnology industry average of 47.08%.
Find out more about AUPH's earnings and revenue performance here.
What are AUPH executives and large shareholders up to?
In the past 12 months, insiders at AUPH have bought more shares than they have sold.
Greg Keenan, Chief Medical Officer of AUPH, was the latest AUPH insider to sell. They sold $68,350.15 worth of AUPH stock on Mar 7, 2025.
Learn more about who owns AUPH shares here.
Can I get consistent income from AUPH stock?
No, Aurinia Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about AUPH
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Place your AUPH purchase
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally sufficient. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact price limit, place a limit order.
Click the Open Trade button and eToro will execute the order.
If you require more info about investing in stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your investment in AUPH
Now that you own some shares in AUPH, you'll want to stay up-to-date on your new company.
Add AUPH to a watchlist to keep tabs on your AUPH stock.
AUPH Feed
How to Buy Stock in Aurinia Pharmaceuticals
To reiterate, here are the 6 steps you need to take to buy Aurinia Pharmaceuticals stock right now:
- Figure out where to buy Aurinia Pharmaceuticals stock
- Create your brokerage account
- Fund your brokerage account
- Analyze Aurinia Pharmaceuticals stock
- Place your AUPH purchase
- Keep tabs on your investment in AUPH
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to monitor your investment in Aurinia Pharmaceuticals, get started below.
More Stock Buying Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.